Philip Patenall

Myelin oligodendrocyte glycoprotein antibodies in neurological disease

Latest Reviews

  • Review Article |

    In the past few years, substantial progress has been made towards effective treatment of Batten disease, a family of paediatric neurodegenerative lysosomal storage disorders. In this Review, the authors discuss new therapies for Batten disease, including cerliponase alfa, the first globally approved agent, and considers promising new therapeutic avenues for future treatments.

    • Tyler B. Johnson
    • , Jacob T. Cain
    • , Katherine A. White
    • , Denia Ramirez-Montealegre
    • , David A. Pearce
    •  & Jill M. Weimer
  • Review Article |

    In this Review, Limousin and Foltynie discuss the current evidence on the long-term outcomes of deep brain stimulation in Parkinson disease and consider the clinical implications of these findings for future use of this therapeutic approach.

    • Patricia Limousin
    •  & Tom Foltynie
  • Review Article |

    Alzheimer disease (AD) pathology is found in almost all adults with Down syndrome (DS), primarily owing to overexpression of APP, present on chromosome 21. Here, Lott and Head examine the commonalities and disparities between DS and AD and highlight findings in DS that can inform research into AD in the general population.

    • Ira T. Lott
    •  & Elizabeth Head
  • Review Article |

    Abnormalities in sensory functions, including tactile, proprioceptive and nociceptive processing, are increasingly recognized in patients with focal dystonias. The authors explore the link between sensory system abnormalities and dystonic motor activity in the context of the 'network model' of dystonia.

    • Antonella Conte
    • , Giovanni Defazio
    • , Mark Hallett
    • , Giovanni Fabbrini
    •  & Alfredo Berardelli
  • Review Article |

    Over the past 20 years, deep brain stimulation (DBS) has transformed the treatment of movement disorders. Now, new therapeutic possibilities for DBS are emerging for other neurological and psychiatric disorders. This Review considers the clinical and scientific advances facilitated by DBS and the crucial questions, challenges and opportunities that face this technology.

    • Andres M. Lozano
    • , Nir Lipsman
    • , Hagai Bergman
    • , Peter Brown
    • , Stephan Chabardes
    • , Jin Woo Chang
    • , Keith Matthews
    • , Cameron C. McIntyre
    • , Thomas E. Schlaepfer
    • , Michael Schulder
    • , Yasin Temel
    • , Jens Volkmann
    •  & Joachim K. Krauss

News & Comment

Milestone

Treatment of multiple sclerosis

The first disease-modifying therapy for relapsing–remitting multiple sclerosis — interferon‑β 1b — was approved by the FDA in 1993. The following 25 years have seen rapid expansion of the therapeutic options as an evolving understanding of the disease has enabled development of therapies with different modes of action.

Naturejobs.com

Nature events Directory